Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Andrys, Rudolf" wg kryterium: Autor


Wyświetlanie 1-5 z 5
Tytuł:
Structure-guided design of N-methylpropargylamino-quinazoline derivatives as multipotent agents for the treatment of Alzheimers disease
Autorzy:
Pulkrabkova, Lenka
Svobodova, Barbora
Panek, Dawid
Nyvltova, Pavlina
Hepnarova, Vendula
Tosnerova, Daniela
Kolcheva, Marharyta
Horak, Martin
Handl, Jiri
Andrys, Rudolf
Rousar, Tomas
Prchal, Lukas
Soukup, Ondrej
Muckova, Lubica
Finger, Vladimir
Capek, Jan
Misiachna, Anna
Karabanovich, Galina
Hrabinova, Martina
Korabecny, Jan
Opis:
Alzheimer’s disease (AD) is a complex disease with an unknown etiology. Available treatments, limited to cholinesterase inhibitors and N-methyl-d-aspartate receptor (NMDAR) antagonists, provide symptomatic relief only. As single-target therapies have not proven effective, rational specific-targeted combination into a single molecule represents a more promising approach for treating AD, and is expected to yield greater benefits in alleviating symptoms and slowing disease progression. In the present study, we designed, synthesized, and biologically evaluated 24 novel N-methylpropargylamino-quinazoline derivatives. Initially, compounds were thoroughly inspected by in silico techniques determining their oral and CNS availabilities. We tested, in vitro, the compounds’ effects on cholinesterases and monoamine oxidase A/B (MAO-A/B), as well as their impacts on NMDAR antagonism, dehydrogenase activity, and glutathione levels. In addition, we inspected selected compounds for their cytotoxicity on undifferentiated and differentiated neuroblastoma SH-SY5Y cells. We collectively highlighted II-6h as the best candidate endowed with a selective MAO-B inhibition profile, NMDAR antagonism, an acceptable cytotoxicity profile, and the potential to permeate through BBB. The structure-guided drug design strategy applied in this study imposed a novel concept for rational drug discovery and enhances our understanding on the development of novel therapeutic agents for treating AD.
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Artykuł
    Wyświetlanie 1-5 z 5

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies